A global phase III randomized controlled trial of EGFR-targeted NIR-PIT for recurrent HNSCC was started in 2018 and is currently ongoing (ClinicalTrials.gov Identifier: NCT03769506). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.